127 related articles for article (PubMed ID: 10947144)
1. Is losartan superior to captopril in reducing all-cause mortality in elderly patients with symptomatic heart failure?
Trojian TH; Jackson EA
J Fam Pract; 2000 Aug; 49(8):759-60. PubMed ID: 10947144
[No Abstract] [Full Text] [Related]
2. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
3. Comparison of losartan and captopril on heart failure-related outcomes and symptoms from the losartan heart failure survival study (ELITE II).
Konstam MA; Neaton JD; Poole-Wilson PA; Pitt B; Segal R; Sharma D; Dasbach EJ; Carides GW; Dickstein K; Riegger G; Camm AJ; Martinez FA; Bradstreet DC; Ikeda LS; Santoro EP;
Am Heart J; 2005 Jul; 150(1):123-31. PubMed ID: 16084158
[TBL] [Abstract][Full Text] [Related]
4. [A-II blocker or ACE inhibitor in heart failure? Captopril can't be beat].
Einecke D
MMW Fortschr Med; 1999 Nov; 141(47):4-5. PubMed ID: 10912155
[No Abstract] [Full Text] [Related]
5. [Current role of angiotensin II antagonists in the treatment of heart failure].
Porcu M; Orrù P
Ital Heart J Suppl; 2000 Sep; 1(9):1213-4. PubMed ID: 11140296
[No Abstract] [Full Text] [Related]
6. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.
Pitt B; Poole-Wilson PA; Segal R; Martinez FA; Dickstein K; Camm AJ; Konstam MA; Riegger G; Klinger GH; Neaton J; Sharma D; Thiyagarajan B
Lancet; 2000 May; 355(9215):1582-7. PubMed ID: 10821361
[TBL] [Abstract][Full Text] [Related]
7. Design of the heart failure endpoint evaluation of AII-antagonist losartan (HEAAL) study in patients intolerant to ACE-inhibitor.
Konstam MA; Poole-Wilson PA; Dickstein K; Drexler H; Justice SJ; Komajda M; Malbecq W; Martinez FA; Neaton JD; Riegger GA; Guptha S
Eur J Heart Fail; 2008 Sep; 10(9):899-906. PubMed ID: 18768350
[TBL] [Abstract][Full Text] [Related]
8. What did we learn from the OPTIMAAL trial? What can we expect from VALIANT?
Dickstein K
Am Heart J; 2003 May; 145(5):754-7. PubMed ID: 12766730
[No Abstract] [Full Text] [Related]
9. [ELITE II. AT1-blockers not better, but more tolerable than ACE-inhibitors].
Berger D
Internist (Berl); 2000 Jan; 41(1):A37. PubMed ID: 10712087
[No Abstract] [Full Text] [Related]
10. Effects of losartan versus captopril on mortality in patients with symptomatic heart failure: rationale, design, and baseline characteristics of patients in the Losartan Heart Failure Survival Study--ELITE II.
Pitt B; Poole-Wilson P; Segal R; Martinez FA; Dickstein K; Camm AJ; Konstam MA; Riegger G; Klinger GH; Neaton J; Sharma D; Thiyagarajan B
J Card Fail; 1999 Jun; 5(2):146-54. PubMed ID: 10404354
[TBL] [Abstract][Full Text] [Related]
11. [The ELITE 2 study].
Mahé I
Presse Med; 2000 Sep; 29(25):1407. PubMed ID: 11036516
[No Abstract] [Full Text] [Related]
12. Erythropoietin levels in heart failure after an acute myocardial infarction: determinants, prognostic value, and the effects of captopril versus losartan.
Belonje AM; Westenbrink BD; Voors AA; von Haehling S; Ponikowski P; Anker SD; van Veldhuisen DJ; Dickstein K
Am Heart J; 2009 Jan; 157(1):91-6. PubMed ID: 19081402
[TBL] [Abstract][Full Text] [Related]
13. Effects of losartan and captopril on left ventricular systolic and diastolic function after acute myocardial infarction: results of the Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan (OPTIMAAL) echocardiographic substudy.
Møller JE; Dahlström U; Gøtzsche O; Lahiri A; Skagen K; Andersen GS; Egstrup K;
Am Heart J; 2004 Mar; 147(3):494-501. PubMed ID: 14999200
[TBL] [Abstract][Full Text] [Related]
14. Does losartan decrease all-cause mortality more than placebo or first-generation ACE inhibitors for patients with moderate to severe heart failure?
LeClair BM
J Fam Pract; 2000 May; 49(5):397. PubMed ID: 10836767
[No Abstract] [Full Text] [Related]
15. Comparison of losartan and captopril in ELITE II.
Hall A
Lancet; 2000 Sep; 356(9232):851; author reply 852-3. PubMed ID: 11022946
[No Abstract] [Full Text] [Related]
16. Haemodynamic, neurohumoral and exercise effects of losartan vs. captopril in chronic heart failure: results of an ELITE trial substudy. Evaluation of Losartan in the Elderly.
Houghton AR; Harrison M; Cowley AJ
Eur J Heart Fail; 1999 Dec; 1(4):385-93. PubMed ID: 10937952
[TBL] [Abstract][Full Text] [Related]
17. Comparison of losartan and captopril in ELITE II.
Lye M
Lancet; 2000 Sep; 356(9232):852; author reply 852-3. PubMed ID: 11022949
[No Abstract] [Full Text] [Related]
18. Randomised comparison of losartan vs. captopril on quality of life in elderly patients with symptomatic heart failure: the losartan heart failure ELITE quality of life substudy.
Cowley AJ; Wiens BL; Segal R; Rich MW; Santanello NC; Dasbach EJ; Pitt B;
Qual Life Res; 2000; 9(4):377-84. PubMed ID: 11131930
[TBL] [Abstract][Full Text] [Related]
19. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE).
Pitt B; Segal R; Martinez FA; Meurers G; Cowley AJ; Thomas I; Deedwania PC; Ney DE; Snavely DB; Chang PI
Lancet; 1997 Mar; 349(9054):747-52. PubMed ID: 9074572
[TBL] [Abstract][Full Text] [Related]
20. ACE inhibitors still the drug of choice for heart failure--and more.
Topol E
Lancet; 1999 Nov; 354(9192):1797. PubMed ID: 10577651
[No Abstract] [Full Text] [Related]
[Next] [New Search]
